Drug Profile


Alternative Names: RU 38086

Latest Information Update: 30 Aug 1994

Price : $50

At a glance

  • Originator Aventis
  • Developer Roussel-Maestretti
  • Class Antisecretories; Cytoprotectives; Small molecules
  • Mechanism of Action Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastric ulcer; Peptic ulcer

Most Recent Events

  • 30 Aug 1994 Discontinued-II for Gastric ulcer in Italy (PO)
  • 30 Aug 1994 Discontinued-II for Gastric ulcer in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top